Abstract
Introduction:
Chronic urticaria (CU) is a common, burdensome mast cell-mediated skin disease. However, little is known about physician estimation of the disease prevalence and clinical impact. This study assessed physicians’ perceptions of CU and compared them with data from peer-reviewed literature.
Methods:
We conducted a cross-sectional, questionnaire-based study distributed worldwide via UCARE (Urticaria Centers of Reference and Excellence) network to 198 UCAREs and forwarded to GPs (general practitioners). Questionnaire data was analyzed using SPSS and subgroup analysis was performed using appropriate non-parametric statistical tests depending on the number of comparison groups and the distribution of the data.
Results:
In total, 234 participants from 46 countries completed the survey [54.3% female, median age: 48.5, interquartile range (IQR) 38.3–58.0 years]. Median age of disease onset reported for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) was 30.0 and 25.0 years, respectively. Median estimated prevalence of CU in adult and pediatric patients was 2.5% and 1.0%, respectively. The most affected aspects of patient life, estimated by physicians, were sleep (CSU), physical activities (CIndU), and mental status (CSU, CIndU). Physicians working at UCARE (78.9% (183/232) vs. non-UCARE (21.1% (49/232) sites differed in their estimation of adult CU prevalence (median: 2.0% vs. 4.5%, p < 0.001), proportion of adult CSU patients among CU patients (median: 70.0% vs. 60.0%, p = 0.027), and proportion of CSU patients with severe impact (median: 50.0% vs. 30.0%, p = 0.042). When asked how confident participants were in their estimations regarding CU prevalence and burden, UCARE experts reported significantly higher median confidence compared to other physicians.
Conclusion:
Although physicians’ estimations of CU prevalence and burden generally align with literature data, non-UCARE physicians may underestimate the burden and overestimate the prevalence. This might affect CU management in primary care potentially leading to a less effective treatment and underscores the need for increased urticaria awareness among non-UCARE physicians via publications, masterclasses, webinars, or other educational initiatives.
Introduction
Chronic urticaria (CU) is an inflammatory, mast cell-mediated skin disease characterized by wheals, angioedema, or both for more than 6 weeks. CU occurs spontaneously (chronic spontaneous urticaria, CSU) and/or is triggered by specific external stimuli such as cold and skin scratching (chronic inducible urticaria, CIndU) (1–3). Most studies reported the point prevalence of CU in adults and children <2% (4), with middle-aged females more frequently affected (5). The point prevalence of CSU, CIndU, or CSU and CIndU in the same patient (CSU + CIndU) in the general population is ∼0.02%–2.7%, 0.05%–1.5%, and 0.05%, respectively, corresponding to approximately 80 million affected individuals worldwide (2, 4, 6–8). The age of onset of CSU is approximately 30–50 years, whereas the median age of onset of CIndU is 20–35 years (3).
CU is debilitating and challenging to manage. Second generation H1-antihistamines at approved or increased doses (up to four-fold standard dosing) lead to complete disease control (Urticaria Control Test, UCT = 16) in less than 10% of CU patients (9). The second-line treatment with omalizumab, an anti-IgE monoclonal antibody, leads to complete disease control in about 30% of patients with antihistamine-refractory CSU (9, 10). High rates of sleep impairment, psychiatric, and other comorbidities in CU patients further contribute to the overall disease burden, considerable impairment of patient's quality of life, and high healthcare costs (11, 12).
Physicians’ perceptions of the disease can influence disease management, impacting treatment decisions, adherence, and overall patient outcomes. For example, underestimation of disease severity and burden can lead to biased or suboptimal care, potentially affecting patient well-being and quality of life (13). However, CU prevalence and burden studies were based primarily on epidemiological studies and data provided by patients. Little is known about how physicians perceive CU or assess CU prevalence and disease impact (3, 14, 15). CU-PAPER (Chronic Urticaria—Physician Estimation of Prevalence and Clinical Impact) is a multicenter, cross-sectional study of Urticaria Centers of Reference and Excellence (UCARE) that aims to address these gaps by assessing physicians’ estimations of the prevalence and clinical impact of CU and comparing them to published data. We also investigated whether different groups of physicians have a different view on CU disease prevalence and burden.
Methods
Data collection
This cross-sectional study used online questionnaire in “REDCap” (Nashville, Tennessee), a secure, web-based software platform designed to support data capture for research studies (https://www.project-redcap.org) (16, 17). The link to the survey was sent to 198 UCARE centers through a UCARE email distribution list. UCARE experts were also asked to forward the questionnaire to GPs who manage patients with urticaria in their respective countries. This project was also publicly presented at the Global Urticaria Forum (GUF) in December 2024 in Berlin, Germany. Attendees were invited to participate via a QR code displayed on a presentation slide. A reminder email was also sent to 365 individual email addresses contained in a UCARE network contact list to increase survey response rates. Responses were collected between September 5, 2024, and February 25, 2025.
Ethics approval
CU-PAPER was approved in 2024 by the Ethics Committee of the Charité — Universitätsmedizin Berlin, Germany (reference EA2/130/24).
Questionnaire
The questionnaire included five different sections (Supplementary Figure S1). The first section asked about professional and demographic information. Section two inquired whether the respondents managed patients with CU in their clinical practice and whether they managed adult patients (>18 years), pediatric patients, or both. The third section included 10 questions about CU: (I) Estimation of the average age of disease onset, asked separately for CSU, CIndU, and CSU + CIndU; (II) level of confidence in their estimations about disease onset; (III) estimation of the prevalence (%) of CU in adults in their country; (IV) estimated proportions of CSU/CIndU among CU patients; and (V) confidence in these prevalence and proportions estimations. The same questions were then asked for pediatric patients. In section four, respondents were asked about their perception of the aspects of a patient's life that were most affected by CSU, CIndU, and CSU + CIndU on a scale from 1 (most affected) to 8 (least affected), what the proportions of low/moderate/high impact of CSU, CIndU, and CSU + CIndU on their patient's lives were, and to indicate how confident they were in their estimations. For respondents who reported having CU, a fifth section asked questions on physicians’ own symptoms including type of CU, disease activity, and most frequent and bothersome symptoms.
Statistical analysis
Minimal sample size calculation was performed using the G*Power software (18). Based on the primary objective, which was to compare physicians’ perception of urticaria prevalence/incidence to the ones reported in the literature, and considering a small to moderate effect size g of the difference between the perceived and the true measure (g = 0.1), an alpha of 5% and a beta of 20%, the minimal sample size would be n = 199. Moreover, based on secondary objectives of comparing subgroups of physicians and finding the correlates of urticaria perception, as the major dependent variables are quantitative, multiple regressions would be used to assess their correlates. Assuming a calculated effect size is f2 = 0.11 (small to moderate effect size) and expecting a squared multiple correlation of 0.1 (R2 deviation from 0) related to the Omnibus test of the multiple regression, the minimum necessary sample is n = 205, considering an alpha error of 5%, a power of 80%, and allowing 20 predictors to be included in the model. Thus, a minimal sample size of 225 physicians was targeted, taking into account possible missing values. Continuous variables were reported as median (IQR) and categorical variables as frequency (%). To examine the estimated impact of CSU, CIndU, and CSU + CIndU on daily life, a one-sample t-test was conducted using the mean of the most impaired domain as a reference value. Higher scores, therefore, indicate that an area was estimated as less affected than the most affected domain. To assess differences in continuous or ordinal variables between independent groups, appropriate non-parametric statistical tests were applied depending on the number of comparison groups and the distribution of the data. The normality of continuous variables was evaluated using the Shapiro–Wilk and Kolmogorov–Smirnov tests. The Mann–Whitney U-Test was used to compare differences between two independent groups when the dependent variable was either ordinal or continuous but did not meet the assumption of normality. The Kruskal–Wallis H Test was employed when comparing more than two independent groups on an ordinal or continuous outcome variable that violated the assumptions of normality and homogeneity of variance. All statistical analyses were conducted using SPSS Version 30.0.0.0 (build 171). A two-sided p-value of less than 0.05 was considered statistically significant. The Figures were created using GraphPad Prism 9 [Version 9.5.0 (525), GraphPad Software, San Diego, California, USA].
Results
Demographic data
In total, 234 participants from 46 countries completed the survey (54.3% female, median age: 48.5, IQR 38.3–58.0 years) (Table 1, Supplementary Figure S2, Supplementary Table S1). Most participants were from Europe (44.9%, 105/234), Asia (37.2%, 87/234), and South America (12.4%, 29/234). Most of them were allergist/clinical immunologists (54.7%, 128/234) or dermatologists (38.9%, 91/234) with a median clinical experience of 20.0 years (IQR 10.0-30.0). Approximately two-thirds (68.1%, 158/232) of participants worked in a university/training hospital with 78.9% of these institutions being a UCARE center. Most participants reported seeing children and adult patients with CU (69.0%, 160/232), whereas 24.1% (56/232) and 4.3% (10/232) reported seeing only adults and children, respectively (Table 1). Of the 226 surveyed physicians, 52.2% (118/226) and 15.5% (35/226) stated that they had been affected by acute urticaria and CU, respectively. Among the 35 physicians affected by CU, 40.0% (14/35) had CSU, 37.1% (13/35) CIndU, and 22.9% (8/35) had both. The median CU duration in affected participants was 5.0 years (IQR 2.0-10.0) (Supplementary Table S3).
Table 1
| Parameter | Results | |
|---|---|---|
| Region, % (n) | Number of physicians who indicated a region of residence | 234 |
| Africa | 1.7 (4) | |
| Asia | 37.2 (87) | |
| Europe | 44.9 (105) | |
| North America | 3.8 (9) | |
| Oceania | 0.0 (0) | |
| South America | 12.4 (29) | |
| Gender, % (n/N) female | 54.3 (127/234) | |
| Age in years, median [(IQR), N] | 48.5 (38.3–58.0), 220 | |
| Age groups in years, % (n) | 25–35 | 16.8 (37) |
| 36–50 | 37.7 (83) | |
| 51–65 | 39.6 (87) | |
| 66 or older | 5.9 (13) | |
| Specialty, % (n) | Total number of replies | 234 |
| Allergy/allergology or allergy/clinical immunology | 54.7 (128) | |
| Dermatology | 38.9 (91) | |
| General practice/primary care | 4.3 (10) | |
| Internal medicine | 1.3 (3) | |
| Pediatrics | 0.9 (2) | |
| Years in clinical practice, median [(IQR), N] | 20.0 (10.0–30.0), 232 | |
| Primary place of work, % (n) | Total number of replies | 232 |
| University/training hospital | 68.1 (158) | |
| Public hospital | 9.1 (21) | |
| Private hospital | 7.3 (17) | |
| Private practice (office) | 13.4 (31) | |
| Other (family physician/private clinic/outpatient clinic/ pharmaceutical Industry/residency program) | 2.1 (5) | |
| Do you see patients with CU, % (n) | Total number of replies | 232 |
| No | 2.6 (6) | |
| Only adult patients | 24.1 (56) | |
| Only pediatric patients | 4.3 (10) | |
| Both adult and pediatric patients | 69.0 (160) | |
| UCARE % (n/N) yes | 78.9 (183/232) | |
| AU personally affected % (n/N) | 52.2 (118/226) | |
| CU personally affected % (n/N) | 15.5 (35/226) | |
Demographic data of participating physicians.
IQR, interquartile range; N, total group size; n, subgroup within the total group; AU, acute urticaria; CU, chronic urticaria; UCARE, urticaria centers of reference and excellence.
Estimation of CU onset and prevalence
Median estimated age of disease onset reported for CSU, CIndU, and CSU + CIndU was 30.0 years (IQR 25.0-40.0), 25.0 years (IQR 20.0-30.0) and 30.0 years (IQR 25.0-35.0), respectively (median confidence: 60.0%, IQR 40.0-75.0). The median estimated prevalence of CU in adult patients was 2.5% (IQR 1.0-5.0). The median estimated proportion of CSU patients among all adult CU patients was 70.0% (IQR 55.0-80.0), the proportion of concomitant CIndU in adults with CSU was estimated to be 30.0% (IQR 20.0-45.0; median confidence: 64.0%, IQR 50.0-75.0). The median estimated prevalence of CU in children was 1.0% (IQR 1.0-3.0). The median estimated proportion of CSU patients among all children affected by CU was 60.0% (IQR 29.8-78.5), and the estimated proportion of concomitant CIndU in children with CSU was 29.5% (IQR 11.0-50.0; median confidence: 57.5%, IQR 32.0-71.0) (Supplementary Table S2).
Estimation of CU burden
For CSU, sleep and mental status were reported by 54.9% and 46.9% of the physicians, respectively, as the most common affected areas. For CIndU, physical activities and mental status were reported by 65.5% and 29.2% of the physicians, respectively, as the most affected areas. For CSU + CIndU patients, sleep and mental status were reported by 50.4% and 40.3% of the physicians, respectively, as the most affected areas (Figure 1).
Figure 1
Estimation of CU burden. * % of physicians who rated the area as most or second most affected. CU, chronic urticaria; CSU, chronic spontaneous urticaria, CIndU, chronic inducible urticaria, CSU + CIndU: Patients affected by both CSU and CIndU.
The most affected areas of a patient's life due to CSU, estimated by physicians, were sleep (mean: 3.0 ± 2.2), mental status (mean: 3.3 ± 2.2), and work/school (mean: 4.2 ± 2.1). The least affected areas were spare time (mean: 5.7 ± 2.0), eating behavior (mean: 5.2 ± 2.3), and appearance (mean: 5.0 ± 2.3) (p < 0.001 for all as compared to the reference, sleep). For CIndU, the most affected domains were physical activities (mean: 2.7 ± 2.3), mental status (mean: 3.9 ± 2.1), and appearance (mean: 4.5 ± 2.1). The greatest differences (relative to the reference, physical activities) were seen in eating behaviour (mean: 5.8 ± 2.2, p < 0.001), spare time (mean: 4.9 ± 2.1), and sleep (mean: 4.9 ± 2.4, p < 0.001) (Supplementary Table S2). As estimated by physicians, the median proportion of patients with severe CSU and CIndU who have experienced an impact on sleep, daily life, work, school, or leisure activities was 45.0% (IQR 25.0-60.0) and 30.0% (IQR 15.0-40.0), respectively.
Estimation of CU prevalence and impact differed based on working at the UCARE, region, patient's age and specialty
Physicians working at UCARE (n = 183/232) vs. non-UCARE physicians (n = 49/232) differed in their estimation of CU prevalence in adults (median: 2.0% vs. 4.5%, p < 0.001) and children (median: 1.0% vs. 2.0%, p = 0.005), proportion of adult CSU patients among CU patients (70.0% vs. 60.5%, p = 0.027), and proportion of CSU patients with severe impact (50.0% vs. 30.0%, p = 0.042). UCARE experts also had significantly higher median confidence in estimating CU prevalence and burden as compared to other physicians (Table 2). Estimated adult CU prevalence differed by continent, with higher estimates reported by participants from Asia (n = 87/234) (median: 3.0%, IQR: 2.0–5.0) than those from Europe (n = 105/234) (median: 2.0%, IQR 1.0–4.3; p = 0.007). Compared to physicians who treat only adult patients (n = 56/232), those who treat both adults and pediatric patients (n = 160/232) showed significantly greater confidence in estimating the age of disease onset (p = 0.002), the percentages of CSU and CIndU in adult patients (p = 0.005), and the percentages of CU patients experiencing an impact on their sleep, daily activities, work, school, or leisure activities (p = 0.004) (Supplementary Table S4). Compared to non-urticaria-specialists [GPs, internists and pediatricians (n = 11/226)], allergists/immunologists (n = 126/226) and dermatologists (n = 89/226) showed significant higher confidence in estimating disease onset (p < 0.001 and p = 0.001), the percentages of CSU and CIndU in adult (allergists/immunologists p = 0.008) and pediatric patients (p = 0.001 and p = 0.029) and the percentages of CU patients experiencing an impact on their sleep, daily activities, work, school, or leisure activities (p=<0.001 and p = 0.007) (Supplementary Table S5). No significant differences were seen in CU prevalence estimation and burden based on respondent's age, clinical experience, place of work, or personal history of urticaria (Supplementary Tables S6–S10).
Table 2
| UCARE | Yes (n = 183) | No (n = 49) | p-value independent-samples Mann–Whitney U-Test | |
|---|---|---|---|---|
| Disease onset CSU (in years) median, (IQR), n | 31.0, (28.0–40.0), 180 | 30.0, (23.8–40.0), 46 | 0.437 | |
| Disease onset CIndU (in years) median, (IQR), n | 25.0, (20.0–30.0), 180 | 25.0, (20.0–30.0), 46 | 0.898 | |
| Disease onset CSU + CIndU (in years) median, (IQR), n | 30.0, (25.0–35.0), 180 | 30.0, (25.0–35.0), 46 | 0.992 | |
| Confidence about disease onset median, (IQR), n | 65.0, (45.0–76.0), 180 | 53.5, (32.0–70.3), 46 | 0.039 | |
| Estimation of prevalence of CU in adult patients (%) median, (IQR), n | 2.0, (1.0–4.0), 172 | 4.5, (2.0–6.0), 44 | <0.001 | |
| Percentage of CSU in CU adult patients median, (IQR), n | 70.0, (60.0–80.0), 172 | 60.5, (40.0–75.0), 44 | 0.027 | |
| Percentage of concomitant CIndU in adults with CSU median, (IQR), n | 30.0, (20.0–40.0), 172 | 34.5, (22.5–50.0), 44 | 0.103 | |
| Confidence about percentages for CSU and CIndU in adults median, (IQR), n | 66.0, (50.0–78.0), 172 | 50.0, (37.0–68.8), 44 | 0.003 | |
| Estimation of prevalence of CU in pediatric patients (%) median, (IQR), n | 1.0, (1.0–2.0), 139 | 2.0, (1.0–5.0), 31 | 0.005 | |
| Percentage of CSU in CU pediatric patients median, (IQR), n | 62.0, (30.0–80.0), 139 | 50.0, (29.0–72.0), 31 | 0.578 | |
| Percentage of concomitant CIndU in pediatric patients with CSU median, (IQR), n | 26.0, (11.0–47.0), 139 | 36.0, (10.0–50.0), 31 | 0.651 | |
| Confidence about percentages for CSU and CIndU in pediatric patients median, (IQR), n | 60.0, (40.0–72.0), 139 | 50.0, (22.0–70.0), 31 | 0.138 | |
| Proportion of patients who have experienced severe impact on sleep, daily life, work, school or leisure activities median, (IQR), n | CSU | 50.0, (30.0–60.0), 178 | 30.0, (20.0–50.0), 42 | 0.042 |
| CIndU | 30.0 (13.8–40.0), 173 | 30.0, (20.0–40.0), 41 | 0.884 | |
| CSU + CIndU | 50.0, (30.0–70.0), 173 | 50.0, (30.0–60.0), 41 | 0.080 | |
| Confidence about percentages for proportion of CU patients have experienced an impact median, (IQR), n | 69.0, (50.0–76.0), 178 | 59.0, (40.0–70.0), 42 | 0.032 | |
Comparisons based on working at the UCARE.
UCARE, urticaria centers of reference and excellence; IQR, interquartile range; n, subgroup within the total group; CSU, chronic spontaneous urticaria; CIndU, chronic inducible urticaria; CSU + CIndU, Patients affected by both CSU and CIndU; CU, chronic urticaria.
Discussion
This study evaluated physicians’ perceptions of prevalence and burden of CU. The results of this study are generally in line with other published data, although physicians working at specialized UCARE centers demonstrate a more realistic assessment regarding the prevalence of CU as well as a more accurate perception of the burden experienced by urticaria patients. Moreover, they reported greater confidence in their estimations compared to physicians not affiliated with UCARE centers. While the estimated prevalence and burden values align with previously published data, it is important to note that they reflect physicians’ perceptions rather than measured epidemiologic data.
The estimates in our study regarding the onset of CSU, CIndU, and CSU + CIndU in the same patient are largely consistent with figures reported in the literature, except for CSU where our study indicates a younger median age of onset: median 30.0 years (IQR 25.0–40.0) vs. literature reports of a median onset age of approximately 42 and 45 years (19, 20).
The estimation of the prevalence of CU among adult patients differed significantly depending on the continent of the physician surveyed. Physicians from Europe as compared to those from Asia estimated a significantly lower median prevalence of CU (2.0% vs. 3.0%). However, these findings align with previously published epidemiological data. Studies conducted in Europe report the point prevalence of CU in the population ranging approximately between 0.2% and 1.0%. In contrast, point prevalence estimates from Asian countries tend to be slightly higher, with values reported between 0.5% and 2.9% (4). This variation may reflect differences in environmental factors, genetic predispositions, or healthcare reporting practices between continents. The median estimated CU prevalence in pediatric patients in our study was 1.0% (IQR 1.0-3.0), which is in line with published data reporting a point prevalence between 0.73% and 1.97% (4).
The findings of this study highlight the substantial impact of CU—CSU and CIndU—on various domains of patients’ daily lives as perceived by treating physicians. Impaired sleep and mental well-being, as well as limitations in work or school activities, were identified as the most severely affected aspects in patients with CSU. These results are consistent with results of previous research showing that sleep impairment is a frequent and burdensome consequence of CSU, along with life impairment due to pruritus and looks (19, 21).
Physicians who treat both pediatric and adult patients with CU exhibit greater confidence than physicians who treat only adult patients specifically concerning the estimation of age of disease onset, the distribution of CSU and CIndU in adult patients, and the perceived impact of the disease on key areas of daily life (e.g., sleep, work, school, everyday activities, and leisure). A possible explanation lies in the broader clinical experience that comes with treating patients of different age groups, overall higher patient volume or specific practice setting.
Allergists/immunologists and dermatologists show significantly higher confidence compared to non-urticaria specialists (GPs, internists, and pediatricians) in all categories, likely because of their focused expertise on managing skin-related conditions including CU (22). To ensure accurate diagnosis and effective treatment of CU, increasing guideline awareness among non-specialist physicians is essential (23).
The significant differences in the estimation of the proportion of patients who have experienced severe impact on sleep, daily life, work, school, or leisure activities due to CSU between physicians working at a UCARE center vs. those who don’t point to the underestimated burden of CSU in a subset of respondents. These findings align with the survey conducted by Mosnaim et al., who found that physicians often underestimate and underreport the severity of CSU in their patients (21). In general, our results show that the estimations made by physicians working at UCARE centers tend to align more with results reported in the published literature and are associated with higher confidence. This may, in part, be explained by the fact that working in specialized urticaria centers includes increased physician interactions with urticaria patients and/or focused education and awareness of urticaria-related guidelines and published data that leads to a more accurate physician assessment.
Although not statistically significant, non-urticaria-specialists tended to estimate a lower proportion of patients experiencing a severe impact on daily life due to CSU, CIndU and CSU + CIndU, which may suggest limited awareness and an underestimation of disease burden. Limited awareness may contribute to an underestimation of the disease's impact on patients’ quality of life. This can result in suboptimal treatment, as a physician who underestimates the severity of the disease may choose a less effective treatment option, which can lead to a poorer treatment outcome as shown by Wolfenden et al. in the treatment of asthma (24). For patients, not feeling understood and taken seriously can lead to increased frustration, lower treatment adherence and therefore delayed achievement of disease control (25). Open communication, a patient centered approach, and shared decision making are crucial parts of the relationship between a patient and physician (26). A treatment tailored to the patient's needs can lead to better disease control and an improved quality of life.
There are strengths and limitations to this study. One strength of this study is its international scope, including participants from 46 countries. This provides a previously unavailable global perspective on how physicians assess CU, although the data may not be generalizable to all continents, especially those under-represented such as north America, Africa and Oceania. An analysis of the participants in our study shows that the majority (68.1%) work at university/training hospitals, of whom 78.7% are affiliated with a UCARE center. To gain a more differentiated understanding of physicians’ perspectives on CU, it would be beneficial to conduct further studies focusing more on GPs and other non-UCARE physicians, as they are often the treating physician for patients with CU (8, 14).
Due to the small number of participants in the non-specialist (n = 11) and pediatric patients only (n = 10) groups, these subgroup analyses were underpowered, and the corresponding results should therefore be interpreted with caution and as preliminary observations rather than definitive results. The reported prevalence and burden values represent physicians’ subjective estimations which may be influenced by recall bias and do not constitute direct epidemiologic measurements. This distinction is essential to avoid overinterpretation of the results. The indirect limitation is a lack of literature data on the impairment of specific areas of daily life caused by CSU + CIndU in the same patient. Further studies in this area would allow to more accurately capture the burden experienced by patients and to better tailor treatment strategies and support services accordingly.
Conclusion
The results of our multicenter, cross-sectional study highlight the need for enhancing awareness of non-UCARE physicians regarding the prevalence and burden of CU. Targeted initiatives may include dissemination of clinical guidelines, educational webinars explaining referral indications, need for shared decision making and workshops on the use of patient reported outcome measurements. Improved physician knowledge of CU and awareness of disease burden may, ultimately, lead to improved CU patient care and an increased likelihood of achieving complete disease control, the main goal of urticaria treatment (27).
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, upon reasonable request.
Ethics statement
CU-PAPER was approved in 2024 by the Ethics Committee of the Charité - Universitätsmedizin Berlin, Germany (reference EA2/130/24).
Author contributions
BMK: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. FA: Data curation, Formal analysis, Software, Validation, Visualization, Writing – review & editing. IC-O: Data curation, Resources, Validation, Writing – review & editing. JEH: Data curation, Resources, Validation, Writing – review & editing. EK: Data curation, Resources, Validation, Writing – review & editing. PHL: Data curation, Resources, Validation, Writing – review & editing. IN: Data curation, Resources, Validation, Writing – review & editing. PS: Data curation, Formal analysis, Methodology, Supervision, Validation, Writing – review & editing. HB: Conceptualization, Investigation, Methodology, Project administration, Supervision, Validation, Writing – review & editing. PK: Conceptualization, Investigation, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The UCARE (Urticaria Centers of Reference and Excellence) network is part of the GA²LEN (Global Allergy and Asthma Excellence Network) and is supported through collaborations, donations, and sponsorships from partner organizations, including the pharmaceutical industry.
Acknowledgments
We would like to express our deepest gratitude to Marcus Maurer, who conceived the idea for this study and inspired all co-authors with his unwavering commitment, wisdom, and passion. With great respect and admiration, we dedicate this manuscript to his memory, honoring his legacy in all that we do. We would also like to thank all our highly motivated medical colleagues who participated in the study and the UCARE Network for their help with disseminating the survey.
Conflict of interest
HB was a speaker/consultant and/or advisor for and/or has received research funding from AbbVie, Almirall, Biocryst, Celltrion, Granular Therapeutics, Novartis, Sanofi Aventis, Sobi and ValenzaBio, outside of the submitted work. PK was a speaker/consultant and/or advisor for and/or has received research funding BioCryst, Insignia, Merus, Novartis, Roche, Sanofi and ValenzaBio, outside of the submitted work. EK is/was recently a speaker/consultant for Menarini and Novartis and received research funding from Almirall. JEH was an advisor/consultant and/or speaker for AbbVie, Apogee, Arcutis, BI, Blueprint Medicines, BMS, Dermavant, Eli Lilly, Galderma, Janssen, LEO, Novartis, Oruka, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB. IC-O: Payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events for Sanofi Aventis outside of the submitted work. PHL was a speaker/consultant and/or advisor for and/or has received research funding from Menarini, Novartis and Sanofi outside of the submitted work.
The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/falgy.2025.1732893/full#supplementary-material
Abbreviations
CIndU, chronic inducible urticaria; CSU, chronic spontaneous urticaria; CSU + CIndU, chronic spontaneous and chronic inducible urticaria in the same patient; CU, chronic urticaria; GP, general practitioner; IQR, interquartile range; UCARE, urticaria centers of reference and excellence; UCT, urticaria control test.
References
1.
Zuberbier T Abdul Latiff AH Abuzakouk M Aquilina S Asero R Baker D et al The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. (2022) 77(3):734–66. 10.1111/all.15090
2.
Kolkhir P Bonnekoh H Metz M Maurer M . Chronic spontaneous urticaria: a review. JAMA. (2024) 332(17):1464–77. 10.1001/jama.2024.15568
3.
Kolkhir P Giménez-Arnau AM Kulthanan K Peter J Metz M Maurer M . Urticaria. Nat Rev Dis Primers. (2022) 8(1):61. 10.1038/s41572-022-00389-z
4.
Fricke J Ávila G Keller T Weller K Lau S Maurer M et al Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. (2020) 75(2):423–32. 10.1111/all.14037
5.
Zuberbier T Balke M Worm M Edenharter G Maurer M . Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. (2010) 35(8):869–73. 10.1111/j.1365-2230.2010.03840.x
6.
Maurer M Hawro T Krause K Magerl M Metz M Siebenhaar F et al Diagnosis and treatment of chronic inducible urticaria. Allergy. (2019) 74(12):2550–3. 10.1111/all.13878
7.
Peck G Hashim MJ Shaughnessy C Muddasani S Elsayed NA Fleischer AB Jr . Global epidemiology of Urticaria: increasing burden among children, females and low-income regions. Acta Derm Venereol. (2021) 101(4):adv00433. 10.2340/00015555-3796
8.
Weller K Maurer M Bauer A Wedi B Wagner N Schliemann S et al Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany. J Eur Acad Dermatol Venereol. (2022) 36(1):91–9. 10.1111/jdv.17724
9.
Kolkhir P Laires PA Salameh P Asero R Bizjak M Košnik M et al The benefit of complete response to treatment in patients with chronic spontaneous urticaria-CURE results. J Allergy Clin Immunol Pract. (2023) 11(2):610–20.e5. 10.1016/j.jaip.2022.11.016
10.
Tharp MD Bernstein JA Kavati A Ortiz B MacDonald K Denhaerynck K et al Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. (2019) 155(1):29–38. 10.1001/jamadermatol.2018.3447
11.
Kolkhir P Bieber K Hawro T Kridin K Ludwig MA Olbrich H et al Mortality in adult patients with chronic spontaneous urticaria: a real-world cohort study. J Allergy Clin Immunol. (2025) 155(4):1290–8. 10.1016/j.jaci.2024.11.036
12.
Gonçalo M Gimenéz-Arnau A Al-Ahmad M Ben-Shoshan M Bernstein JA Ensina LF et al The global burden of chronic urticaria for the patient and society. Br J Dermatol. (2021) 184(2):226–36. 10.1111/bjd.19561
13.
Tang MBY Fatani M Wiggins S Maspero J . Physician perception of disease severity and treatment outcomes for children and adolescents with atopic dermatitis in emerging economies. Dermatol Ther (Heidelb). (2022) 12(4):999–1013. 10.1007/s13555-022-00708-y
14.
Rimoldi M Rossi O Rota N . State of the art of chronic spontaneous urticaria in Italy: a multicentre survey to evaluate physicians’ and patients’ perspectives. BMJ Open. (2016) 6(10):e012378. 10.1136/bmjopen-2016-012378
15.
Cheung LY Lynde CW . Chronic spontaneous urticaria (CSU): Canadian dermatologists’ perspective. J Cutan Med Surg. (2016) 20(4):308–12. 10.1177/1203475416631521
16.
Harris PA Taylor R Thielke R Payne J Gonzalez N Conde JG . Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. (2009) 42(2):377–81. 10.1016/j.jbi.2008.08.010
17.
Harris PA Taylor R Minor BL Elliott V Fernandez M O'Neal L et al The REDCap consortium: building an international community of software platform partners. J Biomed Inform. (2019) 95:103208. 10.1016/j.jbi.2019.103208
18.
Faul F Erdfelder E Buchner A Lang AG . Statistical power analyses using G*power 3.1: tests for correlation and regression analyses. Behav Res Methods. (2009) 41(4):1149–60. 10.3758/BRM.41.4.1149
19.
Maurer M Abuzakouk M Bérard F Canonica W Oude Elberink H Giménez-Arnau A et al The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. (2017) 72(12):2005–16. 10.1111/all.13209
20.
Kovalkova E Fomina D Borzova E Maltseva N Chernov A Serdoteckova S et al Comorbid inducible urticaria is linked to non-autoimmune chronic spontaneous urticaria: CURE insights. J Allergy Clin Immunol Pract. (2024) 12(2):482–90.e1. 10.1016/j.jaip.2023.11.029
21.
Mosnaim G Patil D Kuruvilla M Hetherington J Keal A Mehlis S . Patient and physician perspectives on disease burden in chronic spontaneous urticaria: a real-world US survey. Ann Allergy Asthma Immunol. (2025) 134(3):315–23.e3. 10.1016/j.anai.2024.11.028
22.
Kolkhir PV Olisova OY Kochergin NG Sulaimanov SA . Chronic urticaria: diagnostic approach practiced by medical specialists and general practitioners of Russia. RJSKD. (2015) 18(1):45–51. 10.17816/dv36963
23.
Cherrez A Maurer M Weller K Calderon JC Simancas-Racines D Cherrez Ojeda I . Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador. World Allergy Organ J. (2017) 10(1):21. 10.1186/s40413-017-0150-7
24.
Wolfenden LL Diette GB Krishnan JA Skinner EA Steinwachs DM Wu AW . Lower physician estimate of underlying asthma severity leads to undertreatment. Arch Intern Med. (2003) 163(2):231–6. 10.1001/archinte.163.2.231
25.
Nguyen GC LaVeist TA Harris ML Datta LW Bayless TM Brant SR . Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. (2009) 15(8):1233–9. 10.1002/ibd.20883
26.
Joosten EA DeFuentes-Merillas L de Weert GH Sensky T van der Staak CP de Jong CA . Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom. (2008) 77(4):219–26. 10.1159/000126073
27.
Maurer M Augustin M Bauer S Ekanayake-Bohlig S Kircher P Knöll A et al Modelling of patient journey in chronic spontaneous urticaria: increasing awareness and education by shorten patients’ disease journey in Germany. J Eur Acad Dermatol Venereol. (2024) 38(11):2093–101. 10.1111/jdv.19940
Summary
Keywords
chronic inducible urticaria, chronic spontaneous urticaria, disease burden, physician estimation, prevalence
Citation
Kern BM, Aulenbacher F, Cherrez-Ojeda I, Hawkes JE, Kocatürk E, Li PH, Nasr I, Salameh P, Bonnekoh H and Kolkhir P (2026) Physician estimation of the prevalence and clinical impact of chronic urticaria: results of the global, multicenter UCARE CU-PAPER study. Front. Allergy 6:1732893. doi: 10.3389/falgy.2025.1732893
Received
29 October 2025
Revised
05 December 2025
Accepted
12 December 2025
Published
12 January 2026
Volume
6 - 2025
Edited by
Kiran V. Godse, Padmashree Dr. D.Y. Patil University, India
Reviewed by
Vikash Paudel, Patan Academy of Health Sciences, Nepal
John Reed, Oxford University Hospitals NHS Trust, United Kingdom
Updates
Copyright
© 2026 Kern, Aulenbacher, Cherrez-Ojeda, Hawkes, Kocatürk, Li, Nasr, Salameh, Bonnekoh and Kolkhir.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Pavel Kolkhir pavel.kolkhir@charite.de
†These authors share last authorship
ORCID Felix Aulenbacher orcid.org/0009-0000-2105-6060 Ivan Cherrez-Ojeda orcid.org/0000-0002-1610-239X Jason E. Hawkes orcid.org/0000-0001-5870-181X Emek Kocatürk orcid.org/0000-0003-2801-0959 Philip H. Li orcid.org/0000-0002-9155-9162 Iman Nasr orcid.org/0000-0003-0346-9675 Hanna Bonnekoh orcid.org/0000-0002-3567-0149 Pavel Kolkhir orcid.org/0000-0001-5380-8132
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.